Journal article
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease
Parkinsonism & related disorders, Vol.92, pp.15-21
11/2021
DOI: 10.1016/j.parkreldis.2021.10.010
PMID: 34656902
Abstract
We sought to examine whether levels of soluble alpha-synuclein (α‐syn), amyloid-beta (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau), as measured in cerebrospinal fluid (CSF), are associated with changes in brain volume in Parkinson's disease.
We assessed the 4-year change in total brain volume (n = 99) and baseline CSF α‐syn, Aβ42, p-tau, and t-tau of Parkinson Progression Markers Initiative participants. We used linear mixed models to assess the longitudinal effect of baseline CSF biomarkers on total and regional brain volume and thickness as well as linear regression for cross-sectional analyses at baseline and year 2. All models were adjusted for age and gender; brain volume models also adjusted for baseline intracranial volume. Bonferroni correction was applied.
The 4-year change in total brain volume was −21.2 mm3 (95% confidence interval, −26.1, −16.3). There were no significant associations between the 4-year change in total brain volume and baseline levels of any CSF biomarker (all p-values > 0.05). On cross-sectional analyses, CSF Aβ42 was linearly associated with total brain volume at baseline (R2 = 0.60, p = 0.0004) and at year 2 (R2 = 0.66, p < 0.0001), with CSF Aβ42 < 1100 pg/ml, the threshold for brain amyloid pathology, associated with smaller total brain volume at baseline (p = 0.0010) and at year 2 (p = 0.0002). CSF α‐syn was linearly associated with total brain volume at baseline (R2 = 0.58, p = 0.0044) but not at year 2 (R2 = 0.58, p = 0.1342).
Reduction in soluble Aβ42 is associated with lower total brain volume in Parkinson's disease.
•CSF Aβ42 levels at baseline are linearly associated with brain volume in Parkinson’ disease.•CSF Aβ42 < 1100 pg/ml was associated with smaller brain volume compared with CSF Aβ42 > 1100 pg/ml.•Brain amyloidosis was not associated with brain atrophy at 4 years of follow-up.
Details
- Title: Subtitle
- Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease
- Creators
- Alberto J Espay - James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USADavid-Erick Lafontant - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, United StatesKathleen L Poston - Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USAChelsea Caspell-Garcia - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, United StatesLuca Marsili - James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USAHyunkeun Ryan Cho - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, United StatesColin McDaniel - Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USANessa Kim - Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USAChristopher S Coffey - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, United StatesAbhimanyu Mahajan - James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USAKariem Ezzat - Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, SwedenAndrea Sturchio - James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USAParkinson's Progression Markers Initiative
- Resource Type
- Journal article
- Publication Details
- Parkinsonism & related disorders, Vol.92, pp.15-21
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/j.parkreldis.2021.10.010
- PMID
- 34656902
- ISSN
- 1353-8020
- eISSN
- 1873-5126
- Grant note
- DOI: 10.13039/100000864, name: Michael J. Fox Foundation for Parkinson's Research
- Language
- English
- Date published
- 11/2021
- Academic Unit
- Biostatistics
- Record Identifier
- 9984214957702771
Metrics
7 Record Views